cardiovascular-agents and Psychotic-Disorders

Cognitive impairment is a core deficit across psychotic disorders, the causes and therapeutics of which remain unclear. Epidemiological observations have suggested associations between cognitive dysfunction in psychotic disorders and cardiovascular risk factors, but an underlying etiology has not been established.. Neuropsychological performance using the Brief Assessment of Cognition in Schizophrenia (BACS) was assessed in 616 individuals of European ancestry (403 psychosis, 213 controls). Polygenic risk scores for coronary artery disease (PRS. Higher PRS

Topics: Adult; Cardiovascular Agents; Cognitive Dysfunction; Coronary Artery Disease; Female; Humans; Male; Neuropsychological Tests; Psychotic Disorders; White People

Psychiatric disorders are associated with an increased risk of cardiovascular diseases and may result in additional risk of non-adherence. No data on the influence of concomitant psychiatric drug use on patients' beliefs and persistence related to cardiovascular medication are available. The objective of this study was to assess to what extent the use of concomitant psychiatric drugs is associated with patients' beliefs about and persistence with chronic cardiovascular medication.. An observational study in patients using cardiovascular medication was conducted. A mailed questionnaire containing socio-demographical questions and a measure of beliefs about medication (Beliefs about Medicines Questionnaire - specific) was sent to patients selected from fifteen participating pharmacies. Persistence was evaluated based on pharmacy records.. Of the 1547 included patients, 551 responded to key questions in the questionnaire and were included for beliefs about medication analysis. In concomitant users of psychiatric drugs significantly higher necessity (17.0 vs. 16.0) and higher concerns (14.3 vs. 13.3), as well as higher proportion of ambivalent (34.5% vs. 25.6%) and lower proportion of indifferent patients (24.1% vs. 33.0%) were found compared with non-users (p < 0.05). 65.2% (n = 1009) of patients were persistent on all their cardiovascular drugs. There was no significant association between concomitant use of psychiatric drugs and non-persistence (OR = 1.2; 95% CI 0.9-1.5).. Concomitant use of psychiatric drugs was found to be associated with increased beliefs about the necessity of and concerns about cardiovascular medication. Clinicians caring for cardiovascular patients should give additional attention to identifying patients' beliefs about medication among those concomitantly using psychiatric drugs.

Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cardiovascular Agents; Cardiovascular Diseases; Cross-Sectional Studies; Drug Therapy, Combination; Female; Health Knowledge, Attitudes, Practice; Humans; Male; Medication Adherence; Middle Aged; Psychotic Disorders; Surveys and Questionnaires; Young Adult

Topics: Cardiovascular Agents; Hallucinogens; Humans; Mental Disorders; Muscle Relaxants, Central; Psychotic Disorders

Topics: Biperiden; Cardiovascular Agents; Mental Disorders; Muscle Relaxants, Central; Parkinson Disease; Psychoses, Substance-Induced; Psychotic Disorders

Topics: Cardiovascular Agents; Ergot Alkaloids; Lysergic Acid Diethylamide; Mental Disorders; Oxytocics; Paranoid Disorders; Psychotic Disorders

Topics: Cardiovascular Agents; Ergot Alkaloids; Lysergic Acid Diethylamide; Mental Disorders; Oxytocics; Psychotic Disorders; Rorschach Test

Topics: Amines; Cardiovascular Agents; Humans; Mental Disorders; Muscle Relaxants, Central; Poisoning; Psychoses, Substance-Induced; Psychotic Disorders

Topics: Alcohol Withdrawal Delirium; Cardiovascular Agents; Mental Disorders; Muscle Relaxants, Central; Pregnanediol; Pregnanediones; Psychoses, Alcoholic; Psychotic Disorders; Sodium; Succinates

Topics: Cardiovascular Agents; Central Nervous System Stimulants; Ergot Alkaloids; Humans; Lysergic Acid Diethylamide; Mental Disorders; Psychotic Disorders

Topics: Art; Cardiovascular Agents; Ergot Alkaloids; Mental Disorders; Phenethylamines; Psychotic Disorders; Shared Paranoid Disorder

Topics: Cardiovascular Agents; Ergot Alkaloids; Lysergic Acid Diethylamide; Mental Disorders; Niacin; Nicotinic Acids; Psychotic Disorders

Topics: Cardiovascular Agents; Hallucinations; Muscarinic Antagonists; Muscle Relaxants, Central; Parkinson Disease; Psychotic Disorders; Salts

Topics: Bipolar Disorder; Cardiovascular Agents; Humans; Mental Disorders; Muscle Relaxants, Central; Psychomotor Agitation; Psychotic Disorders